Literature DB >> 25648895

13-Methylarachidonic acid is a positive allosteric modulator of endocannabinoid oxygenation by cyclooxygenase.

Shalley N Kudalkar1, Spyros P Nikas2, Philip J Kingsley1, Shu Xu1, James J Galligan1, Carol A Rouzer3, Surajit Banerjee4, Lipin Ji2, Marsha R Eno2, Alexandros Makriyannis2, Lawrence J Marnett5.   

Abstract

Cyclooxygenase-2 (COX-2) oxygenates arachidonic acid (AA) and the endocannabinoids 2-arachidonoylglycerol (2-AG) and arachidonylethanolamide to prostaglandins, prostaglandin glyceryl esters, and prostaglandin ethanolamides, respectively. A structural homodimer, COX-2 acts as a conformational heterodimer with a catalytic and an allosteric monomer. Prior studies have demonstrated substrate-selective negative allosteric regulation of 2-AG oxygenation. Here we describe AM-8138 (13(S)-methylarachidonic acid), a substrate-selective allosteric potentiator that augments 2-AG oxygenation by up to 3.5-fold with no effect on AA oxygenation. In the crystal structure of an AM-8138·COX-2 complex, AM-8138 adopts a conformation similar to the unproductive conformation of AA in the substrate binding site. Kinetic analysis suggests that binding of AM-8138 to the allosteric monomer of COX-2 increases 2-AG oxygenation by increasing kcat and preventing inhibitory binding of 2-AG. AM-8138 restored the activity of COX-2 mutants that exhibited very poor 2-AG oxygenating activity and increased the activity of COX-1 toward 2-AG. Competition of AM-8138 for the allosteric site prevented the inhibition of COX-2-dependent 2-AG oxygenation by substrate-selective inhibitors and blocked the inhibition of AA or 2-AG oxygenation by nonselective time-dependent inhibitors. AM-8138 selectively enhanced 2-AG oxygenation in intact RAW264.7 macrophage-like cells. Thus, AM-8138 is an important new tool compound for the exploration of allosteric modulation of COX enzymes and their role in endocannabinoid metabolism.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Allosteric Regulation; Cyclooxygenase (COX); Endocannabinoid; Enzyme Kinetics; Site-directed Mutagenesis

Mesh:

Substances:

Year:  2015        PMID: 25648895      PMCID: PMC4367288          DOI: 10.1074/jbc.M114.634014

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  The structural basis of endocannabinoid oxygenation by cyclooxygenase-2.

Authors:  Alex J Vecchio; Michael G Malkowski
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

2.  (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2.

Authors:  Kelsey C Duggan; Daniel J Hermanson; Joel Musee; Jeffery J Prusakiewicz; Jami L Scheib; Bruce D Carter; Surajit Banerjee; J A Oates; Lawrence J Marnett
Journal:  Nat Chem Biol       Date:  2011-11       Impact factor: 15.040

3.  Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen.

Authors:  Kelsey C Duggan; Matthew J Walters; Joel Musee; Joel M Harp; James R Kiefer; John A Oates; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2010-09-01       Impact factor: 5.157

4.  Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer.

Authors:  Liang Dong; Alex J Vecchio; Narayan P Sharma; Brice J Jurban; Michael G Malkowski; William L Smith
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

5.  Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids.

Authors:  Hechang Zou; Chong Yuan; Liang Dong; Ranjinder S Sidhu; Yu H Hong; Dmitry V Kuklev; William L Smith
Journal:  J Lipid Res       Date:  2012-04-30       Impact factor: 5.922

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 7.  Chemical probes of endocannabinoid metabolism.

Authors:  Jacqueline L Blankman; Benjamin F Cravatt
Journal:  Pharmacol Rev       Date:  2013-03-19       Impact factor: 25.468

Review 8.  Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  Chem Rev       Date:  2011-09-19       Impact factor: 60.622

9.  Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation.

Authors:  Daniel J Hermanson; Nolan D Hartley; Joyonna Gamble-George; Naoko Brown; Brian C Shonesy; Phillip J Kingsley; Roger J Colbran; Jeffrey Reese; Lawrence J Marnett; Sachin Patel
Journal:  Nat Neurosci       Date:  2013-08-04       Impact factor: 24.884

10.  ω-Alkynyl lipid surrogates for polyunsaturated fatty acids: free radical and enzymatic oxidations.

Authors:  William N Beavers; Remigiusz Serwa; Yuki Shimozu; Keri A Tallman; Melissa Vaught; Esha D Dalvie; Lawrence J Marnett; Ned A Porter
Journal:  J Am Chem Soc       Date:  2014-07-29       Impact factor: 15.419

View more
  12 in total

1.  Interactions of 2-O-arachidonylglycerol ether and ibuprofen with the allosteric and catalytic subunits of human COX-2.

Authors:  Liang Dong; Hechang Zou; Chong Yuan; Yu H Hong; Charis L Uhlson; Robert C Murphy; William L Smith
Journal:  J Lipid Res       Date:  2016-04-08       Impact factor: 5.922

Review 2.  Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2.

Authors:  William L Smith; Michael G Malkowski
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

3.  A seven-step plan for becoming a moderately rich and famous biochemist.

Authors:  William L Smith
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

4.  Competition and allostery govern substrate selectivity of cyclooxygenase-2.

Authors:  Michelle M Mitchener; Daniel J Hermanson; Erin M Shockley; H Alex Brown; Craig W Lindsley; Jeff Reese; Carol A Rouzer; Carlos F Lopez; Lawrence J Marnett
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-21       Impact factor: 11.205

5.  Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site.

Authors:  Michael C Goodman; Shu Xu; Carol A Rouzer; Surajit Banerjee; Kebreab Ghebreselasie; Marco Migliore; Daniele Piomelli; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2018-01-11       Impact factor: 5.157

6.  Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry.

Authors:  Michael J Lucido; Benjamin J Orlando; Alex J Vecchio; Michael G Malkowski
Journal:  Biochemistry       Date:  2016-02-19       Impact factor: 3.162

7.  Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit.

Authors:  Liang Dong; Chong Yuan; Benjamin J Orlando; Michael G Malkowski; William L Smith
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

8.  Different Fatty Acids Compete with Arachidonic Acid for Binding to the Allosteric or Catalytic Subunits of Cyclooxygenases to Regulate Prostanoid Synthesis.

Authors:  Liang Dong; Hechang Zou; Chong Yuan; Yu H Hong; Dmitry V Kuklev; William L Smith
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

9.  Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone.

Authors:  Benjamin J Orlando; Michael G Malkowski
Journal:  J Biol Chem       Date:  2016-05-20       Impact factor: 5.157

10.  Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics.

Authors:  Mary E Konkle; Anna L Blobaum; Christopher W Moth; Jeffery J Prusakiewicz; Shu Xu; Kebreab Ghebreselasie; Dapo Akingbade; Aaron T Jacobs; Carol A Rouzer; Terry P Lybrand; Lawrence J Marnett
Journal:  Biochemistry       Date:  2015-12-31       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.